Yarrow Bioscience (NASDAQ:YARW) Research Coverage Started at BTIG Research

BTIG Research began coverage on shares of Yarrow Bioscience (NASDAQ:YARW) in a research report sent to investors on Monday, Marketbeat.com reports. The firm issued a buy rating and a $58.00 price target on the stock.

Separately, TD Cowen began coverage on Yarrow Bioscience in a research report on Tuesday, July 28th. They set a “buy” rating for the company. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $58.00.

Yarrow Bioscience Stock Performance

NASDAQ YARW opened at $37.70 on Monday. Yarrow Bioscience has a 1-year low of $14.02 and a 1-year high of $46.95.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.